ABSTRACT Background: Mandatory fortification, prevalent supplement use, and public health guidelines recommending periconceptional supplementation have increased folic acid intakes in North American pregnant women. However, the effects of increased folic acid intakes during pregnancy on maternal and cord blood folate concentrations have not been well established. Objectives: In this prospective study, we determined maternal and cord blood concentrations of folate and unmetabolized folic acid (UMFA) in a cohort of pregnant Canadian women and their newborns and examined the effect of maternal intakes of folate and folic acid and fetal genetic variants in folate metabolism on folate status. Design: Folate and folic acid intakes of 368 Canadian pregnant women were assessed in early (0-16 wk) and late (23-37 wk) pregnancy. Blood concentrations of folate and UMFA were measured with the use of immunoassays and liquid chromatography-mass spectrometry, respectively, in maternal samples in early pregnancy (12-16 wk), at delivery (28-42 wk), and in cord blood. Four fetal genetic variants of the 5,10-methylenetetrahydrofolate reductase (MTHFR) and dihydrofolate reductase (DHFR) genes were assessed for their association with cord blood concentrations of folate and UMFA. Results: Geometric mean (95% CI) maternal red blood cell (RBC) folate concentrations were 2417 nmol/L (2362, 2472 nmol/L ) and 2793 nmol/L (2721, 2867 nmol/L ) in early pregnancy and at delivery, respectively. The mean (95% CI) cord RBC folate concentration was 2689 nmol/L (2614, 2765 nmol/L). UMFA was detectable in .90% of maternal and cord plasma samples. Although 3 fetal MTHFR and DHFR genetic variants had no effect, the fetal MTHFR 677TT genotype was associated with significantly lower cord serum (P = 0.03) and higher cord RBC (P = 0.02) folate concentrations than those of the wild type. Conclusions: Notwithstanding differences in assays, maternal and cord RBC folate and plasma UMFA concentrations were higher than previously reported values. Functional ramifications of high folate and UMFA concentrations in maternal and fetal circulation warrant additional investigation because an excess folate status may affect long-term health outcomes of the offspring. This study was registered at www.clinicaltrials.gov as NCT02244684.
INTRODUCTION
Folate mediates the transfer of one-carbon units that are involved in nucleotide biosynthesis and biological methylation reactions and, hence, plays an important role in DNA synthesis, stability, repair, and methylation (1) . The metabolic demand for folate is increased during pregnancy because of the rapid rate of maternal and fetal cellular growth and development (2) . An inadequate folate status during pregnancy is associated with adverse pregnancy and birth outcomes including megaloblastic anemia and neural tube defects (2) . In light of overwhelmingevidenceforaprotectiveeffectofpericonceptionalfolic acid supplementation on risk of neural tube defects, folic acid fortification of the food supply became mandatory in 1998 in the United States and Canada (2, 3) , which led to a 26-47% reduction in the rates of neural tube defects (4, 5) . In addition, women of reproductive age are recommended to consume 400 mg folic acid/d from fortified foods, supplements, or both 2-3 mo before conception and during pregnancy (2) . Studies from Canada and the United States have reported that the majority of women now consume supplements containing folic acid before and during pregnancy (6, 7) . These facts suggest that North American pregnant women and their fetuses are likely exposed to high amounts of folate and folic acid.
Longitudinal analyses of the folate status of Americans in the NHANES reported serum and red blood cell (RBC) 11 folate concentrations were 2.5 and 1.5 times prefortification values, respectively (8) . In the Canadian Health Measures Survey, w35% of Canadian women 20-39 y of age had RBC folate concentrations greater than the 97th percentile of the NHANES (1999) (2000) (2001) (2002) (2003) (2004) ) data (9) . Finally, after folic acid fortification, most individuals have measurable concentrations of unmetabolized folic acid (UMFA) in blood, which are likely attributable to high synthetic folic acid intakes (10) (11) (12) (13) . Concerns have been raised over whether high synthetic folic acid intakes and circulating UMFA concentrations pose a health risk (14) . These concerns include the masking of vitamin B-12 deficiency (15) , accelerated tumor progression (16, 17) , aberrant DNA methylation (18) , and diminished natural killer cell cytotoxicity (19) . Furthermore, periconceptional high folic acid intake has been linked to aberrant embryonic developments in mice (20, 21) and humans (22) , increased risks of asthma and respiratory tract infections (23) and insulin resistance and obesity in children (24) , perturbation in DNA methylation programming (25) , and increased cancer risk in rodent offspring (26) . Therefore, a more complete understanding of blood folate and UMFA concentrations in both maternal and fetal compartments in a population with mandatory folic acid fortification and widespread folic acid supplement use is necessary. This understanding will help to assess whether current folic acid fortification and supplementation policies provide sufficient coverage to yield maximal protection against neural tube defects without creating undue risk.
The current study assessed maternal and cord blood concentrations of folate and UMFA in a cohort of pregnant Canadian women and their newborninfantsanddeterminedtheeffectofmaternalintakesofdietary folate and supplemental folic acid on maternal and cord blood concentrations of folate and UMFA. Because previous studies suggested that blood folate concentrations and, specifically, UMFA may be influencedbygeneticvariantsinfolatemetabolism (27, 28) ,theeffectof 4variants in fetal5,10-methylenetetrahydrofolate reductase(MTHFR) and dihydrofolate reductase (DHFR) genes on cord blood concentrations of folate and UMFA was also examined.
METHODS

Subjects and study design
All procedures and protocols were reviewed and approved by St. Michael's Hospital Research Ethics Board, and written informed consent was obtained from all women during the initial study visit. Between November 2010 and January 2012, 368 healthy women between the ages of 18 and 45 y with an uncomplicated singleton pregnancy between 12 and 16 wk of gestation were recruited to participate in the PREFORM (Prenatal Folic Acid Exposure on DNA Methylation in the Newborn Infant) study (clinicaltrials.gov: NCT02244684). The aim of the PREFORM study is to determine the effects of maternal intakes of folate and folic acid on DNA methylation of mononuclear cells (MNCs) in cord blood. The study design and subject characteristics have been reported in detail previously (29) . Briefly, women who were attending a prenatal clinic visit were recruited from obstetrician offices at St. Michael's Hospital, which is situated in the downtown core of Toronto, Canada. St. Michael's Hospital serves a demographically diverse inner city population and delivers .3000 neonates annually. At enrollment, participants completed a Baseline Demographic and Health Questionnaire that was based on the Canadian Community Health Survey, Cycle 2.2 (30) , to collect information regarding demographics and health status as described previously (29) . Women in the study delivered between April 2011 and August 2012. At birth, infant anthropometric information was recorded.
Assessment of dietary and supplemental intakes
Maternal dietary intakes of folate and other one-carbon nutrients during early and late pregnancy were captured with the use of a 110-item semiquantitative Block food-frequency questionnaire (FFQ; NutritionQuest) that was administered during the first (12-16 wk of gestation) and second (35-37 wk of gestation) study visits as described previously (29) . Briefly, the Block FFQ is designed to capture the consumption of specific foods and beverages in the previous 3 mo and, specifically, between 0 and 16 wk of gestation (early pregnancy) and between 23 and 37 wk of gestation (late pregnancy) in the current study. The Block FFQ has been validated for B-vitamin intake in a sample of Ontarian women of reproductive age (34-36 y) (31) . The median de-attenuated Pearson correlation coefficient between the Block FFQ and two 24-h recalls was reported to be 0.76 for folate (31) . Vitamin-supplement use was assessed for 3 time periods as follows: preconception (30 d before pregnancy), early pregnancy (conception to 16 wk of gestation), and late pregnancy (23-37 wk of gestation) with the use of the baseline demographic questionnaire and the Block FFQ. Information on the type, frequency, and dose of folic acid supplement was obtained for the preconception and early pregnancy time points. In late pregnancy, information on the type and frequency, but not the dose, of folic acid supplement use was collected.
Sample collection and processing
Maternalvenousbloodwasdrawnfromeachsubjectduringearly pregnancy (12-16 wk of gestation) and at delivery (28-42 wk of gestation). Participants were not instructed to fast before blood collection, and the time of the last meal or supplement use was recorded. The mean 6 SD length of time that food or supplements were consumed before blood draw was 5.2 6 2.4 h. At delivery, #20 mL venous blood was also obtained from the umbilical cord. Blood samples were collected in evacuated tubes containing EDTA for plasma homocysteine and RBC folate analyses or containing a clot activator and gel for serum separation for the determination of serum folate. Plasma and serum were separated from whole blood within 2 h of collection, and serum and RBC folate and plasma homocysteine were determined immediately in the St. Michael's Hospital Core Laboratory. The remaining plasma was stored at 2808C until additional analysis for plasma UMFA. Approximately 8 mL cord blood was used for MNC extraction with the use of the ACCUSPIN System-Histopaque 1077 System (Sigma-Aldrich). A total of 200 mL RNAprotect Cell Reagent (Qiagen Sciences) was added to cell pellets before freezing. Cell pellets were stored at 2808C until DNA extraction. 
Serum and RBC folate assays
Plasma UMFA assay
The preparation of standards and samples for the determination of plasma UMFA was conducted in the co-authors' (SA, DLO) laboratory and analyzed at the Analytic Facility for Bioactive Molecules at The Hospital for Sick Children, Toronto, Canada, with the use of stable-isotope-dilution liquid-chromatographytandem mass spectrometry according to methods published by Pfeiffer et al. (33) . Standard curves were prepared from spectrometrically verified stock solutions of folic acid and folic acid-13C5 (Merck Eprova). On the basis of a signal:noise ratio .3:1, the limit of detection was 0.2 nmol/L. With the use of duplicate sample preparations from 71 subjects, intra-assay CVs for plasma UMFA for concentrations ,0.9, 0.9-2.0, and .2.0 nmol/L were 12.3%, 16.8%, and 4%, respectively. The interassay accuracy and precision were also determined with the use of levels II (certified value: 1.05 6 0.16 nmol/L) and III (1.07 6 0.24 nmol/L) of SRM 1955 (n = 5 runs). The means 6 SDs (CV) of level II and III reference material were 1.24 6 0.12 nmol/L (9.5%) and 1.19 6 0.12 nmol/L (10.0%), respectively.
Plasma homocysteine assay
Total plasma homocysteine [an inverse indicator of folate status (2)] concentrations were determined through the use of a quantitative, enzymatic assay with the Synchron LX20 System (Beckman Coulter,) in the St. Michael's Hospital Core Laboratory. Intra-assay and interassay CVs were , 5.5% and ,2%, respectively.
DNA isolation and genotyping
DNA from cord blood MNCs was isolated with the use of the DNAIsolationKitforMammalianBlood(RocheDiagnostics).The extracted DNA was .20 kb in all instances, was free of RNA contamination, and had an A 260/280 ratio between 1.8 and 2.0. Weexaminedtheeffectsof2singlenucleotidepolymorphismsin the gene encoding MTHFR, which catalyzes the irreversible conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate (14) , and 2 variants in the gene encoding DHFR, which converts folic acid and dihydrofolate to tetrahydrofolate (14) , on cord blood folate and homocysteine concentrations. The MTHFR 677C.T (rs1801133) and 1298A.C (rs1801131) polymorphisms were genotyped with the use of TaqMan genotyping assays on an ABI Vii7 Biosystem (Applied Biosystems) as described previously (34) . The DHFR rs1643649 located in intron 3 was genotyped with the use of the iPLEX Assay on a MassARRAY platform (Sequenom) at the Centre for Applied Genomics as described previously (35) . The DHFR 19-base pair (bp) insertion/ deletion (rs70991108) was assessed with the use of polymerase chain reaction with fluorescent hybridization as previously described (28) .
Statistical analysis
Maternal and cord serum and RBC folate and plasma UMFA concentrations were log transformed to meet the assumptions of normality. The smallest detectable concentration (i.e., the limit of detection) of plasma UMFA was 0.2 nmol/L. For the analyses, plasma UMFA concentrations ,0.2 nmol/L were considered undetectable and were assigned a value of zero. Descriptive statistics were reported as means and geometric means for normally distributed and transformed variables, respectively, with corresponding 95% CIs. Categorical variables were reported as numbers and percentages. t tests and chi-square tests were used to determine differences between supplement users and nonusers with respect to continuous and categorical variables, respectively. Correlations between dietary and blood variables were assessed with the use of Pearson's tests. A least-squares regression and generalized least-squares regression were used to identify predictors of cord and maternal concentrations. Potential predictors from the literature for maternal blood concentrations included maternal age, BMI, educational level, ethnicity, dietary folate equivalents, and supplemental folic acid intake in early pregnancy and the fasting time before blood draw (9, 36) . Potential predictors for cord blood concentrations included maternal dietary and supplemental folate intakes in late pregnancy, maternal and cord folate concentrations, parity, and infant MTHFR677C.T genotype. Differences in cord blood variables in fetal genotypes were adjusted for ethnicity (white or nonwhite), gestational age at delivery, and dietary folate and supplemental folic acid intakes in late pregnancy. A logistic regression was used to determine differences in percentages of detectable UMFA ($0.2 nmol/L) in fetal genotypes.
All tests were 2 tailed, and a , 0.05 was considered statistically significant. P values for tests of interactions between fetal genotype and quartile of maternal RBC folate were adjusted with the use of the false-discovery rate adjustment with the PROC MULTTEST statement (SAS Institute Inc.) to maintain an overall significance of 0.05. Statistical analyses were performed with the use of SAS version 9.3 software (SAS Institute Inc.). All available data were included in analyses, and the sample size for each analysis was reported.
RESULTS
Characteristics of study subjects and newborn infants
Detailed information on the PREFORM study design and participants has been published previously (29) . The majority of subjects were Caucasian, university graduates, nulliparous, and nonsmokers, and the mean 6 SD age was 32 6 5 y ( Table 1) . Maternal characteristics were not significantly different between folic acid-containing supplement users and nonusers. Newborn gestational age, birth weight, length, and head circumference were within normal ranges ( Table 2 ). There were no differences in the gestational age at birth, sex of the infant, birth weight, birth length, or head circumference between newborns from mothers who used supplements throughout pregnancy and those from mothers who did not use supplements throughout pregnancy.
Dietary and supplemental intakes of folate and folic acid
Detailed information on dietary and supplemental intakes of folate and folic acid of PREFORM study participants has been published previously (29) . Briefly, mean 6 SD maternal dietary folate intakes (DFEs) (including naturally occurring folate and folic acid added as a fortificant) were 483 6 203 mg DFE/d in early pregnancy and 465 6 186 mg DFE/d in late pregnancy. Ninetythree percent and 90% of women reported the use of folic acidcontaining supplements in early and late pregnancy, respectively; 83% of women reported daily doses of $1 mg folic acid in early pregnancy (29) . The median (IQR) maternal supplemental folic acid intake was 1000 mg/d (1000-1000 mg/d) during early pregnancy. Self-reported supplemental vitamin use in late pregnancy was only reported as a categorical variable (yes or no), and therefore, no dosages of supplemental folic acid intake were reported for late pregnancy.
Maternal and cord blood folate and homocysteine concentrations
All subjects had serum and RBC folate concentrations above established deficiency cutoffs [,7 and ,305 nmol/L, respectively (2)] ( Table 3) 23 (7) 20 (6) 3 (1) 1 Means (95% CIs) or geometric means (back-transformed 95% CIs) are reported for continuous variables; n (%) is reported for categorical variables. Skewed distributions were log transformed before the analysis. t tests were used to compare continuous variables, and chi-square tests were used to compare categorical variables, except for Fisher's exact test, which was used for maternal smoking status. P values were for the testing of the null hypothesis of no difference between supplement users and nonusers. Maternal sample-size range was 353-364 because of missing values. Maternal serum folate concentrations significantly decreased during pregnancy, whereas RBC folate and plasma homocysteine concentrations significantly increased during pregnancy (P , 0.0001). Cord serum folate concentrations were 64% higher than maternal serum folate concentrations at delivery (P , 0.0001). In contrast, cord RBC folate concentrations were 3.8% lower than maternal RBC folate concentrations were at delivery (P = 0.01). Cord plasma homocysteine concentrations were 20% lower than maternal plasma homocysteine concentrations at delivery (P , 0.0001). Relations between maternal and cord blood remained the same when the statistical analyses were performed in subjects who had a complete set of blood samples at each time point (i.e., early pregnancy, delivery, and cord blood).
Serum or RBC folate or plasma homocysteine concentrations during early pregnancy were not significantly different between women who took folic acid-containing supplements and thosewho did not. In contrast, women who supplemented in late pregnancy had significantly higher serum (P , 0.0001) and RBC folate (P , 0.0001) concentrations at delivery than those of nonusers, whereas plasma homocysteine concentrations were not significantly different between the 2 groups. 1 Means (95% CIs) or geometric means (back-transformed 95% CIs) are reported for continuous variables. Skewed distributions were transformed before the analysis. t tests were used to compare continuous variables. The sample-size range for maternal blood at 12-16 wk of gestation was 342-345 because of missing values. The sample-size range for maternal blood at delivery was 285-293 because of missing values. The sample-size range for cord blood was 246-285 because of missing values. P values are for the testing of the null hypothesis of no difference between supplement users and nonusers. For total subjects, values with different superscript letters within each folate biomarker were significantly different from corresponding values at different time points as follows: maternal blood values at delivery were significantly different from those at 12-16 wk of gestation, P , 0.0001; cord blood values were significantly different from corresponding maternal blood values at delivery, P , 0.02; and cord blood values were significantly different from corresponding maternal blood values at 12-16 wk of gestation, P , 0.0001. RBC, red blood cell; UMFA, unmetabolized folic acid. 2 For maternal concentrations at 12-16 wk of gestation, supplement use was during early pregnancy, and for maternal concentrations at delivery and cord blood concentrations, supplement use was during late pregnancy. 3 Participant recruitment occurred at 12-16 wk of gestation when maternal blood was collected.
Serum (P , 0.0001) and RBC folate (P = 0.0002) concentrations were also significantly higher in cord blood from mothers who supplemented in late pregnancy than in cord blood from nonusers. Plasma homocysteine concentrations were significantly lower in cord blood from mothers who took supplements in late pregnancy than in cord blood from nonusers (P = 0.03).
Maternal and cord blood UMFA concentrations
During early pregnancy, maternal plasma UMFAwas detectable ($0.2 nmol/L) in 97% of women (range: undetectable to 244 nmol/L) ( Table 3 ). In maternal samples collected during early pregnancy with detectable UMFA, the median (IQR) proportion of plasma UMFA to total serum folate was 3.09% (1.90-8.93%). Plasma UMFA was detectable in 93% of cord blood samples (range: undetectable to 15 nmol/L). The median (IQR) proportion of plasma UMFA to total serum folate in detectable cord blood samples was 1.34% (0.92-82.12%). Cord plasma UMFA concentrations were 72% lower than maternal plasma UMFA concentrations during early pregnancy (P , 0.0001). The proportion of plasma UMFA that made up total serum folate was greater for maternal blood than for cord blood (P , 0.0001).
Maternal plasma UMFA concentrations during early pregnancy were not significantly different between subjects who took folic acid-containing supplements and those who did not. Plasma UMFA concentrations were not significantly higher in cord blood from mothers who supplemented in late pregnancy than in cord blood from nonusers (P = 0.07).
RBC folate and plasma UMFA concentrations were weakly correlated in maternal blood during early pregnancy (r = 0.18, P = 0.0009) but not in cord blood (r = 0.08, P = 0.23). In contrast, serum folate and plasma UMFA concentrations were strongly correlated in maternal blood during early pregnancy (r = 0.81, P , 0.0001) and were weakly correlated in cord blood (r = 0.24, P = 0.0002).
Association of maternal dietary and supplemental intakes with blood concentrations
Previously reported maternal dietary intakes of folate (i.e., naturally occurring and folic acid added as a fortificant) (29) were not associated with maternal folate concentrations either in early pregnancy or at delivery (data not shown). In unadjusted general linear models, folic acid supplement use in early pregnancy predicted maternal serum and RBC folate concentrations (both P = 0.03), but not plasma UMFA concentrations, in early pregnancy (Table 4) . However, only serum folate concentrations remained significant after adjustment for covariates (P = 0.0007). Maternal dietary intakes of folate in late pregnancy were not associated with cord folate concentrations (data not shown).
Association between maternal and cord blood concentrations
In unadjusted general linear models, maternal concentrations of serum and RBC folate and plasma homocysteine at delivery were positively associated with concentrations of the corresponding biomarker in the cord blood (all P , 0.0001) ( Table 5) . Adjustment for additional covariates did not change the associations; in all 3 analyses, adjusted estimates were similar to unadjusted estimates.
Cord blood folate and homocysteine concentrations on the basis of infant genotype
All genotypes were shown to be in Hardy-Weinberg equilibrium (P . 0.22), indicating that the observed genotype frequencies were not different from the expected frequencies derived from the Hardy-Weinberg equation. The minor-allele frequency for all genotypes was .5% (MTHFR677C.T rs1801133: 29.9%; MTHFR1298A.C rs1801131: 30.5%; DHFR intron 3 single nucleotide polymorphism rs1643649: 22.5%; DHFR 19-bp insertion/deletion rs70991108: 46.2%). The MTHFR 1298A.C or DHFR 19-bp insertion/deletion genotype in cord blood MNCs was not significantly associated with serum and RBC folate, plasma UMFA, or plasma homocysteine concentrations or the proportion of detectable plasma UMFA in cord blood (Supplemental Table  1 ). However, with the MTHFR 677C.T variant, cord serum folate concentrations were higher in wild-type CC newborns than in homozygous TT newborns (P = 0.03) ( Table 6 ). In contrast, higher RBC folate concentrations were shown in cord blood in homozygous TT newborns than in wild-type CC newborns (P = 0.02). With respect to the DHFR intron 3 polymorphism, cord plasma homocysteine concentrations differed across genotypes (P = 0.01).
TABLE 4
Regression analyses of the association of maternal supplemental folic acid intake (mg/d) in early pregnancy with maternal concentrations of serum and RBC folate, plasma UMFA, and plasma homocysteine at recruitment (12-16 wk of gestation) 1 
Maternal blood variable
Unadjusted model
Adjusted model 1 Data were analyzed with the use of general linear models. The adjusted model was designed with the use of a stepwise regression analysis with entry and stay cutoffs at 0.15 and was additionally adjusted for the time of the last meal before blood draw, maternal age, BMI, educational level, ethnicity, parity, and maternal dietary total folate and folic acid intakes in early pregnancy. A regression analysis was performed with maternal supplemental fatty acid intake in early pregnancy as independent variables and maternal concentrations of serum and RBC folate, UMFA, and homocysteine as dependent variables. Maternal serum and RBC folate and plasma UMFA concentrations were log transformed before the analysis. The sample-size range was 283-322 because of missing values. RBC, red blood cell; UMFA, unmetabolized folic acid.
Cord plasma homocysteine concentrations were lower in homozygous TT newborns than in heterozygous CT newborns (P = 0.036), whereas there was no difference between the wild-type CC and heterozygous CT variant. The effect of interactions between infant genotype and quartiles of maternal RBC folate concentrations at delivery on serum and RBC folate, plasma UMFA, and plasma homocysteine concentrations in cord blood were determined. However, after adjusting for multiple testing with the use of the false-discovery rate in PROC MULTTEST statement, no significant interactions were shown (data not shown).
DISCUSSION
In a cohort of demographically diverse pregnant women from Southern Ontario, Canada, .90% of whom were taking a periconceptional folic acid-containing supplement with the most common dose of 1 mg/d, no subject was folate deficient. Most importantly, all women had RBC folate concentrations .1000 nmol/L in early pregnancy, which is the estimated concentration below which risk of neural tube defects begins to rise (37) . Serum and RBC folate concentrations in early pregnancy and at delivery were in ranges generally considered to be high. Different assays used across published studies and the limitations associated with these assays precluded a direct comparison of our data with others (32, (38) (39) (40) (41) . Nevertheless, RBC folate concentrations measured with the use of the Elecsys immunoassay (Roche Diagnostics) in our subjects were well above those previously reported (7, 27, (42) (43) (44) (45) (46) (47) . (7), the recently reported median (95% CI) RBC folate concentrations measured with the use of the Quantaphase II assay (Bio-Rad Laboratories), which was adjusted for the microbiologic assay for folic acid users and nonusers, were 1628 nmol/L (1589, 1695 nmol/L) and 1041 nmol/L (962, 1184 nmol/L) , respectively. The observed higher RBC folate concentrations in the current study were likely related to the higher proportion of women who consumed folic acid supplements during the first trimester (93% compared with w55%), the higher dose of folic acid (mean daily dose of 1000 mg compared with a median daily dose of 800 mg) in the current study than in the NHANES study, and the differences in analytic methods as will be discussed.
Maternal and cord RBC folate concentrations in our study were much higher, whereas maternal and cord plasma homocysteine concentrations were generally comparable to or lower, than those previously reported in countries without mandatory or with voluntary folic acid fortification only (27, 42, 43, 45, 46, (48) (49) (50) (51) . These 1 Data were analyzed with the use of general linear models. The adjusted model was designed with the use of a stepwise regression analysis with entry and stay cutoffs at 0.15 and was additionally adjusted for other maternal and cord folate variables, parity, and infant MTHFR 677C.T genotype. A regression analysis was performed with maternal concentrations of serum and RBC folate and plasma homocysteine at delivery as independent variables and cord concentrations of serum and RBC folate and plasma homocysteine as dependent variables. Cord serum and RBC folate concentrations were log transformed before the analysis. The sample-size range was 223-275 because of missing values. MTHFR, 5,10-methylenetetrahydrofolate reductase; RBC, red blood cell. Serum and RBC folate and UMFAwere log transformed before the analysis. Folate and folic acid concentrations are reported as geometric means (95% CIs), and homocysteine concentrations are reported as means (95% CIs). Folate, folic acid, and homocysteine concentrations were compared with the use of an ANCOVA with Tukey's post hoc adjustment. UMFA was compared with the use of logistic regression. All models were adjusted for ethnicity, gestational age at delivery, and dietary folate and supplemental folic acid intake in late pregnancy. The sample-size range was 238-285 because of missing values. DHFR, dihydrofolate reductase; MTHFR, 5,10-methylenetetrahydrofolate reductase; RBC, red blood cell; UMFA, unmetabolized folic acid. 2 Limit of detection: $0.2 nmol/L. differences were likely due to the mandatory folic acid fortification and ubiquitous folic acid supplement use in our cohort as well as analytic differences in folate measurements (32, 39) .
Consistent withpreviousstudies (27, 42, 46) ,weobserved higher serum folate and lower plasma homocysteine concentrations in cord blood than in maternal blood at delivery. In contrast with previous studies (27, 42, 52) , cord RBC folate concentrations were 3.8% lower than maternal RBC folate concentrations at delivery. Serum and RBC folate concentrations were significantly higher, whereas plasma homocysteine concentrations were significantly lower, in cord blood from mothers taking folic acid supplements in late pregnancy than in cord blood from nonusers.
Plasma UMFA was detectable in .90% of maternal and umbilical cord blood samples. Folic acid intake as little as 280 mg saturates the capacity of DHFR, which is a critical step in folic acid metabolism (53) and results in its appearance unaltered in the circulation (10, 43) . Plasma UMFA has been previously detected in pregnant women and umbilical cord from countries with a lower periconceptional folic acid supplement use or without mandatory folic acid fortification (43, 46) . Therefore, it was not surprising that maternal and cord plasma UMFA concentrations in the current study were higher than those previously reported (43, 46) . Consistent with a previous study (46) , the lower concentration and percentage of plasma UMFA that contributed to total cord blood folate and a weak or no correlation between plasma UMFA and serum and RBC folate in cord blood suggested that UMFA does not accumulate in the fetus even with a high folate status and detectable UMFA in mothers. Unlike adults, the fetus has limited folate storage in the liver and must use what is immediately available via the placenta (54) . Therefore, the UMFA that reaches the fetus is likely metabolized to active folate forms in a more-efficient manner.
The MTHFR 677TT genotype had lower cord serum folate but higher cord RBC folate concentrations than did the CC genotype. This observation was consistent with a recent meta-analysis that compared serum and RBC folate across MTHFR 677C.T genotypes with the use of different assays (55) . Studies that used protein-binding assays, including the Roche Elecsys assay, reported higher RBC folate in the TT genotype than in the CC genotype (55) . However, serum folate concentrations followed the expected pattern of decreasing concentrations across genotypes (CC.CT.TT) (55) . Protein-binding assays recover folate species at different affinities than those of a microbiologic assay (56) . Therefore, the higher RBC folate observed in the TT genotype could be explained by the nature of the assay used and the altered folate distribution and composition associated with the T allele. Furthermore, under the conditions of high folate, the enzyme kinetics of the variant MTHFR are similar to those of the wild-type enzyme (57, 58) , and only at low folate concentrations does the functional impact of the MTHFR 677C.T variant become significant (59) . Therefore, in high cord RBC folate concentrations, the MTHFR 677C.T polymorphism may not affect RBC folate concentrations in the direction associated with diminished MTHFR activity. In contrast to higher UMFA concentrations associated with the del/del variant in adults (28) , the fetal DHFR 19-bp insertion/deletion or DHFR intron 3 genotypes had no effect on cord plasma UMFA concentrations. The observed null effect may have been related to the fact that UMFA did not accumulate in cord blood.
The PREFORM study provides a novel opportunity to explore the folate status of demographically diverse group of pregnant women and their newborns in Canada as well as the potential modifying effects of the fetal MTHFR and DHFR genetic variants on cord blood folate and UMFA. However, a comparison of our study findings to those of other reports in the literature was severely limited because of the significant assay-dependent and interlaboratory differences in blood folate measurements, which have been discussed previously (32, (38) (39) (40) (41) . For example, it was shown that the RBC folate measured by the Bio-Rad Quantaphase II immunoassay was w45% lower than that determined by the microbiologic assay (39) . In contrast, we showed RBC folate concentrations measured by the Immulite 2000 immunoassay were higher than those determined by the microbiologic assay (32) . Thus, it is very difficult to make direct comparisons of RBC folate concentrations measured by different assays. Therefore, the observed higher RBC folate concentrations in our study might have been in part due to the Roche Elecsys assay. However, in our hands, RBC folate concentrations measured with the use of the Roche Eleccys method were, on average, 5.3% higher than those measured with the use of the microbiologic assay, with all values within 620%. RBC folate concentrations obtained with the use of these 2 different assays resulted in a Pearson correlation coefficient of 0.90 (P , 0.0001). Another limitation of the current study was that folate concentrations were determined in nonfasting maternal blood samples. Fasted blood samples have been shown to have lower serum folate and plasma UMFA concentrations than those of nonfasted samples (13) , although RBC folate concentrations are not affected by the fasting status.
In conclusion, notwithstanding the limitations associated with comparing RBC folate concentrations measured with the use of different assays, maternal RBC folate concentrations were in the range generally considered to be high in a cohort of representative pregnant women in Canada with mandatory folic acid fortification and a prevalent use of prenatal supplements. UMFAwas detectable in .90% of maternal and cord plasma samples. Both maternal and cord RBC folate and plasma UMFA concentrations were higher than previously reported values from unfortified countries. On the positive side, RBC folate concentrations were well within the range in early pregnancy (determined with the use of the microbiologic assay) associated with protection against neural tube defects (.1000 nmol/L) (37) . However, because of concerns over potential adverse health outcomes (1, 14, (20) (21) (22) (23) (24) , the functional ramifications of the observed high concentrations of folate and UMFA in maternal and fetal circulation in the current study warrant additional investigation. Specifically, the dose of folic acid in prenatal supplements should be reconsidered in light of our findings to provide the optimal health benefits to the growing fetus while avoiding undue risk.
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